Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between Health Access and Quality, Economic Resources, and Patient Empowerment.
Heinz LudwigSusie Novis DurieAngela MecklAxel HinkeBrian DuriePublished in: The oncologist (2020)
Multiple myeloma accounts for 10% of all hematological malignancies and has moved to the forefront of clinical interest because of the significant advances in medical treatment. Diagnosis depends on laboratory tests, imaging, and professional expertise, particularly in patients without a significant M-component. The present data show a substantial worldwide variation in incidence and mortality, that is mainly due (apart from variations due to ethnicity and lifestyle) to disparities in access to and quality of health care, a parameter strongly related to the economic development of individual countries. Improvement of quality of care and, consequently, in outcome is associated with patient empowerment.
Keyphrases
- healthcare
- multiple myeloma
- risk factors
- quality improvement
- end stage renal disease
- case report
- public health
- chronic kidney disease
- cardiovascular events
- metabolic syndrome
- peritoneal dialysis
- high resolution
- type diabetes
- affordable care act
- cardiovascular disease
- physical activity
- palliative care
- social media
- prognostic factors
- health information
- machine learning
- drug induced
- photodynamic therapy
- data analysis
- health insurance
- replacement therapy
- fluorescence imaging